The global demand for Nanobodies Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Nanobodies are a novel class of proprietary therapeutic proteins based on single-domain antibody fragments. It contains the unique structural and functional properties of naturally-occurring heavy-chain antibodies. These are small, recombinantly produced antigen-binding VHH fragments, derived from the Alpaca heavy chain IgG antibody (HCA). Due to their tiny size and unique structure, Nanobodies are ideal building blocks for the generation of novel biological drugs with multiple competitive advantages over other therapeutic molecules. The most common uses of nanobodies are for experiments like immunoprecipitation, or fluorescence microscopy.
The growing biologics and therapeutic research and FDA approval provide many opportunities to investigate nanobodies and their interaction with others, thereby lifting hopes for exploring innovative uses. In recent years, nanobodies have become indispensable therapeutic and research tools due to the growing burden of cancer, immune-mediated inflammatory and other diseases. Nanobodies is a lucrative approach for oncology therapeutics research as it inhibits tumor growth, protects the body against systemic toxicity, and allows solubilization of hydrophobic drug in hydrophilic structures. They are researched against a diverse range of disorders and capable of being employed in various situations. Recognizing the potential, companies engaged in therapeutic research are adopting different collaborative research strategies to develop and commercialize nanobody-based therapeutics.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of nanobodies.
The entire nanobodies market has been sub-categorized into product type, indication and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Product Type
By Distribution Channel
- Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
- Respiratory Syncytial Virus (RSV) Infection
- Rheumatoid Arthritis
- Systemic Lupus Erythematosus
- Immune Mediated Inflammatory Diseases (IMID)
- Chronic Kidney Diseases
- Bone Disorders
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
This section covers regional segmentation which accentuates on current and future demand for nanobodies market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Europe Nanobodies Market By Revenue (USD MN)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the nanobodies market include Novo Nordisk A/S, Merck & Co., Inc., Merck KgaA, AbbVie, Inc., C.H. Boehringer Sohn AG & Ko. KG., Ablynx. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.